Evaluation of the efficacy of Yinqiao Baiyi Decoction in treating mild patients with COVID-19
Not Applicable
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2200006746
- Lead Sponsor
- The First Affiliated Hospital to Henan University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
? Patients with mild COVID-19;
? Age 18-80 years old;
? Voluntarily accept treatment and sign informed consent.
Exclusion Criteria
? delirious, consciousness disorder, dementia, all kinds of mental patients;
? Pregnant and lactating women;
? Patients with active pulmonary tuberculosis, pulmonary abscess and chronic respiratory failure;
? Patients with tumor;
? Patients with severe liver and kidney diseases;
? patients with severe cardiovascular and cerebrovascular diseases;
? those who are taking part in clinical trials of other drugs and are known to be allergic to the treatment drugs.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ucleic acid turning negative time;Nucleic acid conversion rate;
- Secondary Outcome Measures
Name Time Method Cumulative incidence of adverse events;rate to the normal/heavy;Time/rate of the abatement of fever;Time/rate of clinical symptom remission;